Ophthotech reported a net income of $189.1 million, or $5.25 per diluted share, in the third quarter of 2017 compared with a net loss of $60.9 million, or $1.71 per diluted share, in the same quarter of last year.
Quarterly collaboration revenue was $206.7 million compared with $1.7 million in the same period a year ago. The increase was attributed to Ophthotech completing “all deliverables required under its licensing and commercialization agreement with Novartis Pharma AG” and recognizing associated deferred revenue, according to a press release.
General and administrative
Uncategorized